International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis
Open Access
- 28 March 2013
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 121 (13), 2393-2401
- https://doi.org/10.1182/blood-2012-09-458521
Abstract
Systemic mastocytosis (SM) is characterized by accumulation of neoplastic mast cells and is classified into indolent and aggressive forms. The latter include aggressive SM (ASM), mast cell leukemia (MCL), and SM associated with a myeloid neoplasm wherein 1 or both disease compartments exhibit advanced features. These variants, henceforth collectively referred to as advanced SM for the purposes of this report, are typically characterized by organ damage and shortened survival duration. In contrast to indolent SM, in which symptoms are usually managed by noncytotoxic antimediator therapy, cytoreduction is usually necessary for disease control in advanced SM. Unfortunately, current drug treatment of these patients rarely results in complete clinical and histopathologic remissions or improved survival time. Previously defined response criteria were adapted to the heterogeneous presentations of advanced SM and the limited effects of available drugs. However, recent advances in understanding the molecular pathogenesis of SM and the corresponding prospect in targeted therapy make it a priority to modify these criteria. Our current study is the product of an international group of experts and summarizes the challenges in accomplishing this task and forwards a new proposal for response criteria, which builds on prior proposals and should facilitate response evaluation in clinical trials.Keywords
This publication has 52 references indexed in Scilit:
- Mast cell leukemia: identification of a new c‐Kit mutation, dup(501‐502), and response to masitinib, a c‐Kit tyrosine kinase inhibitorEuropean Journal of Haematology, 2012
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Cladribine therapy for systemic mastocytosisBlood, 2003
- Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kitExperimental Hematology, 2003
- Treatment of systemic mast cell disease with 2-chlorodeoxyadenosineLeukemia Research, 2003
- Treatment of adult systemic mastocytosis with interferon‐α: results of a multicentre phase II trial on 20 patientsBritish Journal of Haematology, 2002
- Detection of c-kit point mutation Asp-816 → Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemiaLeukemia Research, 2002
- Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteriaLeukemia Research, 2002
- Diagnostic criteria and classification of mastocytosis: a consensus proposalLeukemia Research, 2001
- Treatment of Systemic Mast-Cell Disease with CladribineNew England Journal of Medicine, 2001